Jove
Visualize
Contact Us

Related Concept Videos

Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
Dysbiosis of the Gut Microbiota01:18

Dysbiosis of the Gut Microbiota

The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.Dysbiosis is often characterized by reduced microbial...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ulcerative Jejunitis in Celiac Disease: A 30-Year US Experience.

The American journal of gastroenterology·2024
Same author

Time Trends and Missed Opportunities in Lipoprotein(a) Testing Amongst Young Patients With ST-Elevation Myocardial Infarction in Western Australia.

Heart, lung & circulation·2024
Same author

Characteristics and Outcomes of Young Patients With ST-Elevation Myocardial Infarction Without Standard Modifiable Risk Factors.

The American journal of cardiology·2023
Same author

Unique features of regulation of sulfate assimilation in monocots.

Journal of experimental botany·2022
Same author

Real World Prescribing Strategies for Patients With an Indication for Oral Anticoagulation Undergoing Percutaneous Coronary Intervention.

Journal of cardiovascular pharmacology and therapeutics·2020
Same author

Detection of mixed-strain infections by FACS and ultra-low input genome sequencing.

Gut microbes·2018
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: May 28, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

Probiotics in clostridium difficile Infection.

Xi Na1, Ciaran Kelly

  • 1Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

Journal of Clinical Gastroenterology
|October 14, 2011
PubMed
Summary

Probiotics like Saccharomyces boulardii and Lactobacillus may help prevent Clostridium difficile infection (CDI) in high-risk patients. However, more extensive research is required to confirm these findings for CDI prevention and treatment.

More Related Videos

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Related Experiment Videos

Last Updated: May 28, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

Area of Science:

  • Microbiology
  • Infectious Diseases
  • Gastroenterology

Background:

  • Clostridium difficile infection (CDI) is a significant nosocomial infection with increasing incidence and severity.
  • Antimicrobial therapy-induced colonic microbiota alterations are implicated in CDI pathogenesis.
  • Probiotics, live beneficial microorganisms, are explored for CDI management.

Purpose of the Study:

  • To review the current literature on probiotics for preventing and treating Clostridium difficile infection.
  • To evaluate the efficacy of commonly studied probiotic agents, including Saccharomyces boulardii, Lactobacillus species, and probiotic mixtures.

Main Methods:

  • Literature review of existing studies and clinical recommendations.
  • Analysis of data on Saccharomyces boulardii, Lactobacillus species, and probiotic mixtures in CDI prevention and treatment.

Main Results:

  • Preliminary evidence suggests Lactobacillus-containing probiotic mixtures and S. boulardii may aid in preventing CDI in high-risk antibiotic recipients.
  • Current findings are based on small, individual studies.

Conclusions:

  • Probiotics show potential in preventing CDI, particularly in antibiotic-treated individuals.
  • Larger, well-controlled studies are necessary to validate the efficacy of probiotics in CDI prevention and treatment and to clarify their role.